Actively Recruiting

Phase Not Applicable
Age: 18Years - 85Years
All Genders
NCT05987852

Hyperbaric Oxygen Therapy for Ulcerative Colitis (HBOT-UC)

Led by Northwestern University · Updated on 2026-01-08

126

Participants Needed

13

Research Sites

190 weeks

Total Duration

On this page

Sponsors

N

Northwestern University

Lead Sponsor

N

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Collaborating Sponsor

AI-Summary

What this Trial Is About

Chronic intestinal hypoxia and accompanying mucosal inflammation is a hallmark of ulcerative colitis (UC). Hyperbaric oxygen therapy (HBOT) involves breathing 100% oxygen under increased atmospheric pressure to increase tissue oxygenation. Two small prospective randomized controlled trials have demonstrated that the delivery of HBOT to UC patients hospitalized for acute moderate to severe flares results in improved remission rates and avoidance of in-hospital progression to biologics, small molecules, or colectomy. In this larger trial the study aims to confirm the treatment benefits of HBOT for hospitalized UC patients and study the immune-microbe mechanisms underpinning treatment response.

CONDITIONS

Official Title

Hyperbaric Oxygen Therapy for Ulcerative Colitis (HBOT-UC)

Who Can Participate

Age: 18Years - 85Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Participants with known or newly diagnosed ulcerative colitis who require hospitalization for an acute moderate to severe flare
  • Age between 18 and 85 years
  • Able to fully participate in all aspects of the trial
  • Consented and able to receive first hyperbaric oxygen therapy session within 48 hours of starting intravenous steroids
  • Agree not to participate in another trial during the active intervention period
Not Eligible

You will not qualify if you...

  • Prior receipt of hyperbaric oxygen therapy as standard care or in a clinical trial
  • Presence of complications requiring urgent surgery
  • Need to start biologic or small molecule treatments before randomization or likely need for rescue therapy within 48 hours after randomization
  • Toxic megacolon
  • Inability to receive intravenous steroids
  • History of failure or exposure to 4 or more classes of advanced therapies
  • Diagnosis or suspicion of Crohn's colitis, indeterminate colitis, ischemic colitis, radiation colitis, diverticular disease with colitis, microscopic colitis, or infectious colitis
  • Use of any investigational drug within 30 days
  • Significant heart, kidney, nervous system, endocrine, lung, or liver problems increasing risk of HBOT toxicity
  • Pregnancy or nursing
  • Unwillingness to complete the HBOT course

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 13 locations

1

University of Alabama Medicine

Birmingham, Alabama, United States, 35233

Actively Recruiting

2

University of Los Angeles Health

Los Angeles, California, United States, 90024

Actively Recruiting

3

University of Miami Health

Miami, Florida, United States, 33136

Actively Recruiting

4

Orlando Health

Orlando, Florida, United States, 32806

Actively Recruiting

5

Northwestern Medicine Lake Forest Hospital

Lake Forest, Illinois, United States, 60045

Actively Recruiting

6

University of Louisville

Louisville, Kentucky, United States, 40202

Actively Recruiting

7

Massachusetts General Hospital

Boston, Massachusetts, United States, 02114

Actively Recruiting

8

Mayo Clinic

Rochester, Minnesota, United States, 55905

Actively Recruiting

9

Dartmouth Hitchcock Medical Center

Lebanon, New Hampshire, United States, 03756

Actively Recruiting

10

Cornell University Medical Center

New York, New York, United States, 10065

Active, Not Recruiting

11

State University of New York Upstate Medical University

Syracuse, New York, United States, 13210

Actively Recruiting

12

Allegheny Health

Pittsburgh, Pennsylvania, United States, 15090

Actively Recruiting

13

University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, United States, 15213

Actively Recruiting

Loading map...

Research Team

Y

Yasmin Pina, BS

CONTACT

M

Mary Beth Tull, MS

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here